{
  "guideline": {
    "id": "PA166104994",
    "name": "Annotation of DPWG Guideline for doxepin and CYP2D6",
    "source": "DPWG",
    "version": 30,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104994",
    "relatedChemicals": [
      {
        "id": "PA449409",
        "name": "doxepin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166302273",
      "name": "Recommendation Annotation PA166302273",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103832,
        "html": "<p>Use 80% of the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</p>\n"
      },
      "implications": [
        "The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of doxepin and the active metabolite nordoxepin."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302286",
      "name": "Recommendation Annotation PA166302286",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103865,
        "html": "<p>Double the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid doxepin. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of doxepin and the active metabolite nordoxepin and an increase in the plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302277",
      "name": "Recommendation Annotation PA166302277",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103836,
        "html": "<p>The guideline does not provide a recommendation for doxepin in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on doxepin."
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302281",
      "name": "Recommendation Annotation PA166302281",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103860,
        "html": "<p>Double the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid doxepin. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of doxepin and the active metabolite nordoxepin and an increase in the plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302272",
      "name": "Recommendation Annotation PA166302272",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103831,
        "html": "<p>Use 80% of the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</p>\n"
      },
      "implications": [
        "The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of doxepin and the active metabolite nordoxepin."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302285",
      "name": "Recommendation Annotation PA166302285",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103864,
        "html": "<p>Double the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid doxepin. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of doxepin and the active metabolite nordoxepin and an increase in the plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302276",
      "name": "Recommendation Annotation PA166302276",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103835,
        "html": "<p>The guideline does not provide a recommendation for doxepin in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on doxepin."
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302280",
      "name": "Recommendation Annotation PA166302280",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103839,
        "html": "<p>Double the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid doxepin. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of doxepin and the active metabolite nordoxepin and an increase in the plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302271",
      "name": "Recommendation Annotation PA166302271",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103830,
        "html": "<p>Use 80% of the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</p>\n"
      },
      "implications": [
        "The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of doxepin and the active metabolite nordoxepin."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302284",
      "name": "Recommendation Annotation PA166302284",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103863,
        "html": "<p>Double the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid doxepin. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of doxepin and the active metabolite nordoxepin and an increase in the plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302275",
      "name": "Recommendation Annotation PA166302275",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103834,
        "html": "<p>The guideline does not provide a recommendation for doxepin in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on doxepin."
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302279",
      "name": "Recommendation Annotation PA166302279",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103838,
        "html": "<p>The guideline does not provide a recommendation for doxepin in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on doxepin."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302270",
      "name": "Recommendation Annotation PA166302270",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103829,
        "html": "<p>Use 40% of the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</p>\n"
      },
      "implications": [
        "The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of doxepin and the active metabolite nordoxepin."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302283",
      "name": "Recommendation Annotation PA166302283",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103862,
        "html": "<p>Double the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid doxepin. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of doxepin and the active metabolite nordoxepin and an increase in the plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302287",
      "name": "Recommendation Annotation PA166302287",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103866,
        "html": "<p>Double the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid doxepin. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of doxepin and the active metabolite nordoxepin and an increase in the plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302274",
      "name": "Recommendation Annotation PA166302274",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103833,
        "html": "<p>Use 80% of the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</p>\n"
      },
      "implications": [
        "The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of doxepin and the active metabolite nordoxepin."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302278",
      "name": "Recommendation Annotation PA166302278",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103837,
        "html": "<p>The guideline does not provide a recommendation for doxepin in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on doxepin."
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302282",
      "name": "Recommendation Annotation PA166302282",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449409",
          "name": "doxepin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103861,
        "html": "<p>Double the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid doxepin. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of doxepin and the active metabolite nordoxepin and an increase in the plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011
    }
  ],
  "version": "2023-12-19-10-38"
}